Is Novo Nordisk Stock a Sell Despite its 10% Price Rally in a Month?
Novo Nordisk NVO shares have climbed 10% in the past month, supported by a mix of certain internal factors and positive market catalysts, which boosted investor confidence.
In early September, Novo Nordisk reported positive real-world data from its REACH study, showing that its blockbuster diabetes injection, Ozempic, outperformed Eli Lilly’s LLY Trulicity in reducing cardiovascular risks among type II diabetes (T2D) patients. Ozempic lowered the risk of major adverse cardiovascular events by 23% and remains the only GLP-1 therapy approved to reduce kidney disease progression and cardiovascular death in patients with diabetes and chronic kidney…
